Novel dengue virus NS2B/NS3 protease inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 2, 2015, Pages 1100-1109

  Wu, Hongmei ^a   Bock, Stefanie ^b   Snitko, Mariya ^b   Berger, Thilo ^a   Weidner, Thomas ^a   Holloway, Steven ^a   Kanitz, Manuel ^c   Diederich, Wibke E ^c   Steuber, Holger ^c,e   Walter, Christof ^b   Hofmann, Daniela ^b   Weißbrich, Benedikt ^b   Spannaus, Ralf ^b   Acosta, Eliana G ^d   Bartenschlager, Ralf ^d   Engels, Bernd ^b   Schirmeister, Tanja ^a   Bodem, Jochen ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE; PROTEINASE INHIBITOR; ANTIVIRUS AGENT; NS3 PROTEASE, DENGUE VIRUS; SERINE PROTEINASE; VIRAL PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING ASSAY; BINDING SITE; CONTROLLED STUDY; CYTOTOXICITY TEST; DENGUE VIRUS; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DISSOCIATION CONSTANT; ENZYME ASSAY; ENZYME INHIBITION; ENZYME PURIFICATION; HEPATITIS C VIRUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROLYSIS; IMMUNOFLUORESCENCE; IN VITRO STUDY; MOLECULAR DOCKING; NONHUMAN; NUCLEOPHILICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; QUANTUM MECHANICS; RADIOIMMUNOPRECIPITATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBSTITUTION REACTION; VERO CELL LINE; VIRUS REPLICATION; WESTERN BLOTTING; CELL LINE; DRUG EFFECTS; ENZYMOLOGY; METABOLISM;

ANTIVIRAL AGENTS; CELL LINE; DENGUE VIRUS; HIV-1; HUMANS; MOLECULAR DOCKING SIMULATION; PROTEASE INHIBITORS; SERINE ENDOPEPTIDASES; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84921410449     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03543-14     Document Type: Article

References (40)

1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI. 2013. The global distribution and burden of dengue. Nature 496:504-507. http: //dx.doi.org/10.1038/nature12060.
2. World Health Organization. November 2012, posting date. Dengue and severe dengue. Fact sheet no. 117 World Health Organization, Geneva, Switzerland.
3. Normile D. 2013. Tropical medicine. Surprising new dengue virus throws a spanner in disease control efforts. Science 342:415. http://dx.doi.org/10 .1126/science.342.6157.415.
4. Messer WB, Gubler DJ, Harris E, Sivananthan K, de Silva AM. 2003. Emergence and global spread of a dengue serotype 3, subtype III virus. Emerg Infect Dis 9:800-809. http://dx.doi.org/10.3201/eid0907.030038.
5. Streit JA, Yang M, Cavanaugh JE, Polgreen PM. 2011. Upward trend in dengue incidence among hospitalized patients, United States. Emerg Infect Dis 17:914-916. http://dx.doi.org/10.3201/eid1705.101023.
6. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, Hunsperger E, Kroeger A, Margolis HS, Martinez E, Nathan MB, Pelegrino JL, Simmons C, Yoksan S, Peeling RW. 2010. Dengue: a continuing global threat. Nat Rev Microbiol 8:S7-S16. http://dx.doi.org /10.1038/nrmicro2460.
7. Endy TP, Anderson KB, Nisalak A, Yoon IK, Green S, Rothman AL, Thomas SJ, Jarman RG, Libraty DH, Gibbons RV. 2011. Determinants of inapparent and symptomatic dengue infection in a prospective study of primary school children in Kamphaeng Phet, Thailand. PLoS Negl Trop Dis 5:e975. http://dx.doi.org/10.1371/journal.pntd.0000975.
8. Luz PM, Vanni T, Medlock J, Paltiel AD, Galvani AP. 2011. Dengue vector control strategies in an urban setting: an economic modelling assessment. Lancet 377:1673-1680. http://dx.doi.org/10.1016/S0140-6736 (11)60246-8.
9. Guzman MG, Kouri G. 2002. Dengue: an update. Lancet Infect Dis 2:33-42. http://dx.doi.org/10.1016/S1473-3099(01)00171-2.
10. Lindenbach BD, Thiel H-J, Rice CM. 2007. Flaviviridae: the viruses and their replication, p 1101-1152. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed, vol 1. Lippincott Williams & Wilkins, Philadelphia, PA.
11. Bera AK, Kuhn RJ, Smith JL. 2007. Functional characterization of cis and trans activity of the flavivirus NS2B-NS3 protease. J Biol Chem 282: 12883-12892. http://dx.doi.org/10.1074/jbc.M611318200.
12. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, ADVANCE Study Team. 2011. Telaprevir for previously untreated chronic hepatitisCvirus infection.NEngl J Med 364:2405-2416. http://dx .doi.org/10.1056/NEJMoa1012912.
13. Poordad F, McCone J, Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP, SPRINT-2 Investigators. 2011. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364:1195-1206. http://dx.doi.org/10.1056/NEJMoa1010494.
14. Matthews SJ, Lancaster JW. 2012. Telaprevir: a hepatitis C NS3/4A protease inhibitor. Clin Ther 34:1857-1882. http://dx.doi.org/10.1016/j .clinthera.2012.07.011.
15. Pearlman BL. 2012. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Infect Dis 12:717-728. http://dx.doi.org/10.1016/S1473-3099(12)70060-9.
16. Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, Dixon RA, Scolnick EM, Sigal IS. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A 85:4686-4690. http://dx.doi.org/10.1073/pnas.85.13.4686.
17. HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. 2012. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Washington, DC. http://aidsinfo.nih.gov.
18. Yang CC, Hsieh YC, Lee SJ, Wu SH, Liao CL, Tsao CH, Chao YS, Chern JH, Wu CP, Yueh A. 2011. Novel dengue virus-specific NS2B/NS3 protease inhibitor, BP2109, discovered by a high-throughput screening assay. Antimicrob Agents Chemother 55:229-238. http://dx.doi.org/10.1128 /AAC.00855-10.
19. Nitsche C, Schreier VN, Behnam MA, Kumar A, Bartenschlager R, Klein CD. 2013. Thiazolidinone-peptide hybrids as dengue virus protease inhibitors with antiviral activity in cell culture. J Med Chem 56:8389-8403. http://dx.doi.org/10.1021/jm400828u.
20. Steuer C, Heinonen KH, Kattner L, Klein CD. 2009. Optimization of assay conditions for dengue virus protease: effect of various polyols and nonionic detergents. J Biomol Screen 14:1102-1108. http://dx.doi.org/10 .1177/1087057109344115.
21. D'Arcy A, Chaillet M, Schiering N, Villard F, Lim SP, Lefeuvre P, Erbel P. 2006. Purification and crystallization of dengue and West Nile virus NS2B-NS3 complexes. Acta Crystallogr Sect F Struct Biol Cryst Commun 62:157-162. http://dx.doi.org/10.1107/S1744309106001199.
22. Noble CG, Seh CC, Chao AT, Shi PY. 2012. Ligand-bound structures of the dengue virus protease reveal the active conformation. J Virol 86:438-446. http://dx.doi.org/10.1128/JVI.06225-11.
23. Grimme S, Antony J, Ehrlich S, Krieg H. 2010. A consistent and accurate ab initio parametrization of density functional dispersion correction (DFT-D) for the 94 elements H-Pu. J Chem Phys 132:154104. http://dx .doi.org/10.1063/1.3382344.
24. Dunning JTH. 1989. Gaussian basis sets for use in correlated molecular calculations. I. The atoms boron through neon and hydrogen. J Chem Phys 90:1007-1023.
25. Vosko SH, Wilk L, Nusair M. 1980. Accurate spin-dependent electron liquid correlation energies for local spin density calculations: a critical analysis. Can J Phys 58:1200-1211. http://dx.doi.org/10.1139/p80-159.
26. Becke AD. 1988. Density-functional exchange-energy approximation with correct asymptotic behavior. Phys RevA 38:3098-3100. http://dx.doi .org/10.1103/PhysRevA.38.3098.
27. Lee C, Yang W, Parr RG. 1988. Development of the Colle-Salvetti cor-relation-energy formula into a functional of the electron density. Phys Rev B Condensed Matter 37:785-789. http://dx.doi.org/10.1103/PhysRevB.37 .785.
28. Becke AD. 1993. Density-functional thermochemistry. III. The role of exact exchange. J Chem Phys 98:5648-5652.
29. Othman R, Kiat TS, Khalid N, Yusof R, Newhouse EI, Newhouse JS, Alam M, Rahman NA. 2008. Docking of noncompetitive inhibitors into dengue virus type 2 protease: understanding the interactions with allosteric binding sites. J Chem Infect Model 48:1582-1591. http://dx.doi.org/10 .1021/ci700388k.
30. Chanprapaph S, Saparpakorn P, Sangma C, Niyomrattanakit P, Hannongbua S, Angsuthanasombat C, Katzenmeier G. 2005. Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sites. Biochem Biophys Res Commun 330:1237-1246. http://dx.doi.org/10.1016/j.bbrc.2005.03.107.
31. Ludewig S, Kossner M, Schiller M, Baumann K, Schirmeister T. 2010. Enzyme kinetics and hit validation in fluorimetric protease assays. Curr Top Med Chem 10:368-382. http://dx.doi.org/10.2174/156802610790725498.
32. Jerabek-Willemsen M, Wienken CJ, Braun D, Baaske P, Duhr S. 2011. Molecular interaction studies using microscale thermophoresis. Assay Drug Dev Technol 9:342-353. http://dx.doi.org/10.1089/adt.2011.0380.
33. Cígler P, Kozísek M, Rezácová P, Brynda J, Otwinowski Z, Pokorná J, Plesek J, Grüner B, Dolecková-Maresová L, Mása M, Sedlácek J, Bodem J, Kräusslich H, Král V, Konvalinka J. 2005. From nonpeptide toward noncarbon protease inhibitors: metallacarboranes as specific and potent inhibitors of HIV protease. Proc Natl Acad Sci U S A 102:15394-15399. http://dx.doi.org/10.1073/pnas.0507577102.
34. Kozisek M, Henke S, Saskova KG, Jacobs GB, Schuch A, Buchholz B, Müller V, Kräusslich HG, Rezacova P, Konvalinka J, Bodem J. 2012. Mutations in HIV-1 gag and pol compensate for the loss of viral fitness caused by a highly mutated protease. Antimicrob Agents Chemother 56: 4320-4330. http://dx.doi.org/10.1128/AAC.00465-12.
35. Reiss S, Rebhan I, Backes P, Romero-Brey I, Erfle H, Matula P, Kaderali L, Poenisch M, Blankenburg H, Hiet MS, Longerich T, Diehl S, Ramirez F, Balla T, Rohr K, Kaul A, Buhler S, Pepperkok R, Lengauer T, Albrecht M, Eils R, Schirmacher P, Lohmann V, Bartenschlager R. 2011. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe 9:32-45. http://dx.doi.org/10.1016/j.chom.2010 .12.002.
36. Chang MH, Gordon LA, Fung HB. 2012. Boceprevir: a protease inhibitor for the treatment of hepatitis C. Clin Ther 34:2021-2038. http://dx.doi.org /10.1016/j.clinthera.2012.08.009.
37. Wu F, Yang X. March 2003. A process for preparing 2-trifluoromethyl-10-oxanone from p-trifluorotoluene and o-mercaptobenzoic acid includes nucleophilic substitution reaction on aryl ring to obtain diaryl thioether, and cyclization reaction with concentrated sulfuric acid. Chinese patent 03115623.
38. Moon JK, Park JW, Lee WS, Kang YJ, Chung HA, Shin MS, Yoon YJ, Park KH. 1999. Synthesis of some 2-substituted-thioxanthones. J Heterocyclic Chem 36:793-798. http://dx.doi.org/10.1002/jhet.5570360336.
39. Müller B, Anders M, Akiyama H, Welsch S, Glass B, Nikovics K, Clavel F, Tervo HM, Keppler OT, Kräusslich HG. 2009. HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity. J Biol Chem 284:29692-29703. http://dx.doi.org/10.1074/jbc.M109.027144.
40. Spannaus R, Bodem J. 2014. Determination of the protease cleavage site repertoire-the RNase H but not the RT domain is essential for foamy viral protease activity. Virology 454-455:145-156. http://dx.doi.org/10 .1016/j.virol.2014.02.013.